Literature DB >> 20233614

Comparison of six bone-graft substitutes regarding to cell seeding efficiency, metabolism and growth behaviour of human mesenchymal stem cells (MSC) in vitro.

Caroline Seebach1, Judith Schultheiss, Kerstin Wilhelm, Johannes Frank, Dirk Henrich.   

Abstract

INTRODUCTION: Various synthetic bone-graft substitutes are used commercially as osteoconductive scaffolds in the treatment of bone defects and fractures. The role of bone-graft substitutes is changing from osteoconductive conduits for growth to an delivery system for biologic fracture treatments. Achieving optimal bone regeneration requires biologics (e.g. MSC) and using the correct scaffold incorporated into a local environment for bone regeneration. The need for an unlimited supply with high quality bone-graft substitutes continue to find alternatives for bone replacement surgery.
MATERIALS AND METHODS: This in vitro study investigates cell seeding efficiency, metabolism, gene expression and growth behaviour of MSC sown on six commercially clinical available bone-graft substitutes in order to define their biological properties: synthetic silicate-substituted porous hydroxyapatite (Actifuse ABX), synthetic alpha-TCP (Biobase), synthetic beta-TCP (Vitoss), synthetic beta-TCP (Chronos), processed human cancellous allograft (Tutoplast) and processed bovines hydroxyapatite ceramic (Cerabone). 250,000 MSC derived from human bone marrow (n=4) were seeded onto the scaffolds, respectively. On days 2, 6 and 10 the adherence of MSC (fluorescence microscopy) and cellular activity (MTT assay) were analysed. Osteogenic gene expression (cbfa-1) was analysed by RT-PCR and scanning electron microscopy was performed.
RESULTS: The highest number of adhering cells was found on Tutoplast (e.g. day 6: 110.0+/-24.0 cells/microscopic field; p<0.05) followed by Chronos (47.5+/-19.5, p<0.05), Actifuse ABX (19.1+/-4.4), Biobase (15.7+/-9.9), Vitoss (8.8+/-8.7) and Cerabone (8.1+/-2.2). MSC seeded onto Tutoplast showed highest metabolic activity and gene expression of cbfa-1. These data are confirmed by scanning electron microscopy. The cell shapes varied from round-shaped cells to wide spread cells and cell clusters, depending on the bone-graft substitutes. Processed human cancellous allograft is a well-structured and biocompatible scaffold for ingrowing MSC in vitro. Of all other synthetical scaffolds, beta-tricalcium phosphate (Chronos) have shown the best growth behaviour for MSC. DISCUSSION: Our results indicate that various bone-graft substitutes influence cell seeding efficiency, metabolic activity and growth behaviour of MSC in different manners. We detected a high variety of cellular integration of MSC in vitro, which may be important for bony integration in the clinical setting. 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20233614     DOI: 10.1016/j.injury.2010.02.017

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  34 in total

1.  Mesenchymal stem cell (MSC) and endothelial progenitor cell (EPC) growth and adhesion in six different bone graft substitutes.

Authors:  J Schultheiss; C Seebach; D Henrich; K Wilhelm; J H Barker; J Frank
Journal:  Eur J Trauma Emerg Surg       Date:  2011-06-07       Impact factor: 3.693

2.  Bone allografts combined with adipose-derived stem cells in an optimized cell/volume ratio showed enhanced osteogenesis and angiogenesis in a murine femur defect model.

Authors:  Johannes M Wagner; Nicolas Conze; Guido Lewik; Christoph Wallner; Jan C Brune; Stephanie Dittfeld; Henriette Jaurich; Mustafa Becerikli; Mehran Dadras; Kamran Harati; Sebastian Fischer; Marcus Lehnhardt; Björn Behr
Journal:  J Mol Med (Berl)       Date:  2019-07-31       Impact factor: 4.599

3.  Alpha-tricalcium phosphate (α-TCP): solid state synthesis from different calcium precursors and the hydraulic reactivity.

Authors:  Gulcin Cicek; Eda Ayse Aksoy; Caner Durucan; Nesrin Hasirci
Journal:  J Mater Sci Mater Med       Date:  2011-03-29       Impact factor: 3.896

4.  Do antiosteoporotic drugs improve bone regeneration in vivo?

Authors:  Maximilian Leiblein; Dirk Henrich; Florian Fervers; Kerstin Kontradowitz; Ingo Marzi; Caroline Seebach
Journal:  Eur J Trauma Emerg Surg       Date:  2019-04-26       Impact factor: 3.693

5.  Multipotential stromal cell abundance in cellular bone allograft: comparison with fresh age-matched iliac crest bone and bone marrow aspirate.

Authors:  Thomas G Baboolal; Sally A Boxall; Yasser M El-Sherbiny; Timothy A Moseley; Richard J Cuthbert; Peter V Giannoudis; Dennis McGonagle; Elena Jones
Journal:  Regen Med       Date:  2014-03-12       Impact factor: 3.806

6.  β-tricalcium-phosphate stimulates the differentiation of dental follicle cells.

Authors:  Sandra Viale-Bouroncle; Brigitte Bey; Torsten E Reichert; Gottfried Schmalz; Christian Morsczeck
Journal:  J Mater Sci Mater Med       Date:  2011-05-22       Impact factor: 3.896

7.  Combination of BMP2 and MSCs significantly increases bone formation in the rat arterio-venous loop model.

Authors:  Gregor Buehrer; Amelie Balzer; Isabel Arnold; Justus P Beier; Carolin Koerner; Oliver Bleiziffer; Andreas Brandl; Christian Weis; Raymund E Horch; Ulrich Kneser; Andreas Arkudas
Journal:  Tissue Eng Part A       Date:  2014-11-07       Impact factor: 3.845

8.  Dynamic culture improves MSC adhesion on freeze-dried bone as a scaffold for bone engineering.

Authors:  Fabiany da Costa Gonçalves; Ana Helena da Rosa Paz; Priscila Schmidt Lora; Eduardo Pandolfi Passos; Elizabeth Obino Cirne-Lima
Journal:  World J Stem Cells       Date:  2012-02-26       Impact factor: 5.326

9.  A comparative evaluation of factors influencing osteoinductivity among scaffolds designed for bone regeneration.

Authors:  Erin L Hsu; Jason H Ghodasra; Amruta Ashtekar; Michael S Nickoli; Sungsoo S Lee; Samuel I Stupp; Wellington K Hsu
Journal:  Tissue Eng Part A       Date:  2013-05-01       Impact factor: 3.845

10.  MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer.

Authors:  Jing Han; Hongbo Qu; Mingli Han; Yichao Ding; Mingwei Xie; Jianguo Hu; Yuanwen Chen; Huaying Dong
Journal:  Oncogene       Date:  2020-12-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.